Dr. Guru Sonpavde, MD (Clinical Assistant Professor, Baylor College of Medicine) reported about an open label, phase II trial of sunitinib (Sunitinib, marketed as Sutent, and previously known as SU11248 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. – Wikipedia) for men with metastatic CRPC (castration resistant prostate cancer) following prior docetaxel chemotherapy.
The subjects of the study were given 50 mg of oral Sunitinib daily for 4 of every 6-week cycle until progression and up to a maximum of 8 cycles. Progression was defined as the first occurrence of any of the following: two distinct new lesions on bone scan, progression of measurable disease by RECIST criteria, worsening of pain by 2 points on the six-point present pain intensity (PPI) scale, urinary tract obstruction, bone-related events or a deterioration of performance s